MedPath
FDA Approval

CISPLATIN

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
BluePoint Laboratories
DUNS: 985523874
Effective Date
December 18, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Cisplatin(1 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Gland Pharma Limited

BluePoint Laboratories

650540227

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CISPLATIN

Product Details

NDC Product Code
68001-609
Application Number
ANDA207323
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 18, 2023
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 9 mg in 1 mL
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
CisplatinActive
Code: Q20Q21Q62JClass: ACTIBQuantity: 1 mg in 1 mL

CISPLATIN

Product Details

NDC Product Code
68001-608
Application Number
ANDA207323
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 18, 2023
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 9 mg in 1 mL
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
CisplatinActive
Code: Q20Q21Q62JClass: ACTIBQuantity: 1 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
© Copyright 2025. All Rights Reserved by MedPath